Physician profile
Morgan Findlay
NPI 1063097798
$2,084.39
in general payments reported to CMS, 2019-2025
15 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $861 · 2024: $489 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.98 |
| Education | $236.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $874.01 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $593.86 | 2023-2025 | Sotyktu |
| Astrazeneca Pharmaceuticals LP | $114.00 | 2023 | Fasenra |
| Taiho Oncology, INC. | $77.17 | 2023-2025 | |
| Baxter Healthcare | $75.83 | 2022 | |
| Ucb, INC. | $60.58 | 2025 | Bimzelx |
| Pfizer INC. | $59.63 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $51.46 | 2022-2025 | Dupixent |
| Organon LLC | $46.04 | 2025 | |
| Lilly USA, LLC | $34.51 | 2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $30.88 | 2022-2023 | |
| Alk-Abello, INC | $19.95 | 2022 | |
| Dermavant Sciences, INC. | $18.05 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $14.95 | 2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Findlay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.